Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy

被引：63

作者：

Amato, Robert J. ^{[1
]}

机构：

[1] Methodist Hosp, Res Inst, Genitourinary Oncol Program, Houston, TX 77030 USA

来源：

CLINICAL GENITOURINARY CANCER | 2007年 / 5卷 / 07期

关键词：

D O I：

10.3816/CGC.2007.n.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Results of preclinical studies and clinical phase I/II trials suggest that the antisense oligodeoxynucleotide and DNA methyltransferase inhibitor MG98 can safely and effectively lead to reactivation of methylation silence tumor suppressor genes. It is possible that daily or continuous dosing of MG98 might be more active and less toxic than intermittent dosing. Combination of MG98 with other agents having completely different mechanisms of action seems reasonable. One clinical trial now under way is evaluating the use of MG98 in combination with interferon-a in patients with advanced renal cell carcinoma (RCC). Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest.

引用

页码：422 / 426

页数：5

共 21 条

[1]

Perspectives in antisense therapeutics [J].

Agrawal, S ;

Iyer, RP .

PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :151-160

[2]

The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine [J].

Alleman, WG ;

Tabios, RL ;

Chandramouli, GVR ;

Aprelikova, ON ;

Torres-Cabala, C ;

Mendoza, A ;

Rodgers, C ;

Sopko, NA ;

Linehan, WM ;

Vasselli, JR .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :7011-7021

[3]

Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues [J].

Arai, Eri ;

Kanai, Yae ;

Ushijima, Saori ;

Fujimoto, Hiroyuki ;

Mukai, Kiyoshi ;

Hirohashi, Setsuo .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (02) :288-296

[4]

Battagli C, 2003, CANCER RES, V63, P8695

[5]

Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO

[6]

2-#

[7]

COFFIN J, 2002, ANN ONCOL, V13, P1699

[8]

Costa DB, 2006, J CLIN ONCOL, V24, p414S

[9]

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks [J].

David, AJ ;

Gelmon, KA ;

Siu, LL ;

Moore, MJ ;

Britten, CD ;

Mistry, N ;

Klamut, H ;

D'Aloisio, S ;

MacLean, M ;

Wainman, N ;

Ayers, D ;

Firby, P ;

Besterman, JM ;

Reid, GK ;

Eisenhauer, EA .

INVESTIGATIONAL NEW DRUGS, 2003, 21 (01) :85-97

[10]

SILENCING OF THE VHL TUMOR-SUPPRESSOR GENE BY DNA METHYLATION IN RENAL-CARCINOMA [J].

HERMAN, JG ;

LATIF, F ;

WENG, YK ;

LERMAN, MI ;

ZBAR, B ;

LIU, S ;

SAMID, D ;

DUAN, DSR ;

GNARRA, JR ;

LINEHAN, WM ;

BAYLIN, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :9700-9704

← 1 2 3 →